Radiopharm director reports 5.33M options holdings
Radiopharm Theranostics Ltd director Noel Donnelly has reported his initial derivative holdings in the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Radiopharm Theranostics Ltd director Noel Donnelly has reported his initial derivative holdings in the company. He holds options to buy 5,333,333 Ordinary Shares at an exercise price of $0.0600 per share, expiring on September 30, 2029, granted on December 16, 2024.
According to the grant terms, 2,666,667 options will vest on September 30, 2026 and 2,666,666 options will vest on September 30, 2027, provided he remains a director on those dates.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Donnelly Noel
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 8,000,000 contracts (Direct)
Footnotes (1)
- F1. Granted on December 16, 2024. 2,666,667 options will vest on September 30, 2026 and 2,666,666 options will vest on September 30, 2027 provided Mr. Donnelly is still a Director on such dates.
Key Figures
Options underlying shares: 5,333,333 shares
Exercise price: $0.0600 per share
First vesting tranche: 2,666,667 options
+3 more
6 metrics
Options underlying shares
5,333,333 shares
Total Ordinary Shares underlying reported options grant
Exercise price
$0.0600 per share
Exercise price for the reported options
First vesting tranche
2,666,667 options
Options vesting on September 30, 2026
Second vesting tranche
2,666,666 options
Options vesting on September 30, 2027
Expiration date
September 30, 2029
Option expiration for the reported grant
Grant date
December 16, 2024
Date the options were granted to Noel Donnelly
Key Terms
Option (right to buy), Ordinary Shares, exercise price, vesting, +1 more
5 terms
Option (right to buy) financial
"security_title: "Option (right to buy)""
exercise price financial
"exercisePrice: "0.0600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"options will vest on September 30, 2026 and September 30, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2029-09-30T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Noel Donnelly report in his Form 3 for RADX?
He reported initial holdings of options to buy 5,333,333 Ordinary Shares of Radiopharm Theranostics at an exercise price of $0.0600 per share, expiring on September 30, 2029, reflecting his existing derivative position as a director.
What is the exercise price of Noel Donnelly’s options in Radiopharm Theranostics (RADX)?
The options reported by Noel Donnelly carry an exercise price of $0.0600 per Ordinary Share. This means he can purchase shares at that fixed price if and when the options vest and he chooses to exercise them before expiration.
How many Radiopharm Theranostics (RADX) options does Noel Donnelly hold and when do they vest?
He holds options over 5,333,333 Ordinary Shares. Of these, 2,666,667 options are scheduled to vest on September 30, 2026 and 2,666,666 options on September 30, 2027, subject to his continued service as a director.
When do Noel Donnelly’s Radiopharm Theranostics (RADX) options expire?
All the options reported in this Form 3 expire on September 30, 2029. He must exercise any vested options before that expiration date; otherwise, the right to purchase shares at $0.0600 per share will lapse.
Were Noel Donnelly’s Radiopharm Theranostics (RADX) options recently granted?
Yes. The footnote explains these options were granted on December 16, 2024. The grant includes two vesting tranches in 2026 and 2027, conditional on Noel Donnelly continuing to serve as a director through those vesting dates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates